Glucocorticoids impair HDL-mediated cholesterol efflux besides increased HDL cholesterol concentration: a proof of concept

Archive ouverte

Bouillet, Benjamin | Gautier, Thomas | Denimal, Damien | Samson, Maxime | Masson, David | Pais de Barros, Jean Paul | Maquart, Guillaume | Xolin, Marion | Grosfeld, Alexandra | Dalle, Héloïse | Vergès, Bruno | Moldes, Marthe | Fève, Bruno

Edité par CCSD ; Oxford Univ. Press -

International audience. Objective: Glucocorticoids (GC) are associated with increased cardiovascular morbidity despite increased HDL-C concentration. HDL-mediated cholesterol efflux, a major anti-atherogenic property of HDL particles, is negatively associated with CVD risk. We aimed to determine whether HDL-mediated cholesterol efflux was influenced by GC. Design: Prospective, observational study. Methods: Lipid parameters, HDL composition, HDL-mediated cholesterol efflux, cholesteryl ester transfer protein, phospholipid transfer protein and lecithin cholesterol acyl-transferase (LCAT) activities were determined in ten patients with giant cell arteritis before and 3 months after GC introduction and in seven control subjects. HDL concentration and composition, HDL-mediated cholesterol efflux and LCAT activity were determined in GC-treated mice. Results: In patients, HDL-C concentration was higher after than before treatment GC-treatment ( P = 0.002), while HDL-mediated cholesterol efflux was decreased ( P = 0.008) and negatively associated with the proportion of cholesteryl ester in HDL ( P = 0.04), independently of CRP. As well, in mice, HDL-C level was increased after GC exposure ( P = 0.04) and HDL-mediated cholesterol efflux decreased ( P = 0.04). GC-treated patients had higher cholesteryl ester content in HDL, higher HDL 2 -to-HDL 3 ratio and higher LCAT activity than before treatment ( P = 0.008, P = 0.02 and P = 0.004, respectively). Conclusions: We report, for the first time, that in patients with giant cell arteritis and mice treated with GC, HDL-mediated cholesterol efflux was impaired by GC besides an increased HDL-C level. This impaired HDL functionality, possibly related to HDL enrichment in cholesteryl ester, could contribute to the increased CVD risk observed in GC-treated patients. Further studies are needed in larger populations, to further decipher the effect of GC on HDL.

Consulter en ligne

Suggestions

Du même auteur

Adipocyte Glucocorticoid Receptor Activation With High Glucocorticoid Doses Impairs Healthy Adipose Tissue Expansion by Repressing Angiogenesis. L'activation du récepteur adipocytaire aux glucocorticoïdes par de fortes doses de glucocorticoïdes altère l'expansion saine du tissu adipeux en réprimant l'angiogenèse

Archive ouverte | Vali, Anna | CCSD

International audience. In humans, glucocorticoids (GCs) are commonly prescribed because of their anti-inflammatory and immunosuppressive properties. However, high doses of GCs often lead to side effects, including ...

Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits

Archive ouverte | Gautier, Thomas | CCSD

International audience. Background and aims: Apolipoprotein (apo) C1 is a 6.6 kDa protein associated with HDL and VLDL. ApoC1 alters triglyceride clearance, and it also favors cholesterol accumulation in HDL, especi...

Effects of glucocorticoids on adipose tissue plasticity Effets des glucocorticoïdes sur la plasticité du tissu adipeux. Effets des glucocorticoïdes sur la plasticité du tissu adipeux

Archive ouverte | Vali, Anna | CCSD

International audience. Glucocorticoids (GCs) play an important role in metabolic adaptation, regulating carbohydrate-lipid homeostasis and the immune system. Because they also have anti-inflammatory and immunosuppr...

Chargement des enrichissements...